Ozempic® (semaglutide) a once-weekly GLP-1 RA receptor agonist

Attend this session to find out more about Ozempic, a once-weekly glucagon-like peptide 1 receptor agonist indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus.

Thursday 15th November 2018

11:15 - 11:30

Product Platform - Workshop

Novo Nordisk Logo

Speakers

Regional Medical Advisor, Novo Nordisk UK

Our site is intended for UK Healthcare Professionals

Are you a UK Healthcare Professional?

We’re sending you to our partner charity’s site. 

DRWF provide information and support for people with diabetes and their friends & families